Morepen submits first U.S. ANDA for CDMO expansion

Morepen submits first U.S. ANDA for CDMO expansion — Morepen Laboratories has filed its first Abbreviated New Drug Application (ANDA) in the U.S., marking a key step in its integrated CDMO strategy. The move strengthens its global footprint and could unlock future revenue streams. First U.S. filing enhances long-term growth prospects in the generics market.

📊 STOCKS: $MOREPENLAB | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #CDMO